JP2024525613A5 - - Google Patents
Info
- Publication number
- JP2024525613A5 JP2024525613A5 JP2024500492A JP2024500492A JP2024525613A5 JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5 JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220016P | 2021-07-09 | 2021-07-09 | |
| US63/220,016 | 2021-07-09 | ||
| US202263316466P | 2022-03-04 | 2022-03-04 | |
| US63/316,466 | 2022-03-04 | ||
| PCT/US2022/073541 WO2023283624A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525613A JP2024525613A (ja) | 2024-07-12 |
| JPWO2023283624A5 JPWO2023283624A5 (https=) | 2025-07-17 |
| JP2024525613A5 true JP2024525613A5 (https=) | 2025-07-17 |
Family
ID=84802101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500492A Pending JP2024525613A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368296A1 (https=) |
| EP (1) | EP4366741A4 (https=) |
| JP (1) | JP2024525613A (https=) |
| KR (1) | KR20240035824A (https=) |
| AU (1) | AU2022309238A1 (https=) |
| CA (1) | CA3226367A1 (https=) |
| IL (1) | IL309912A (https=) |
| MX (1) | MX2024000492A (https=) |
| WO (1) | WO2023283624A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| US20250066776A1 (en) | 2023-04-27 | 2025-02-27 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of chronic kidney disease |
| US20240368596A1 (en) * | 2023-05-05 | 2024-11-07 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008504222A (ja) * | 2003-12-15 | 2008-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 新規の抗ｄｃ−ｓｉｇｎ抗体 |
| PL2121751T3 (pl) * | 2006-12-08 | 2017-07-31 | Lexicon Pharmaceuticals, Inc. | Przeciwciała monoklonalne przeciwko ANGPTL3 |
| PE20141114A1 (es) * | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| JP2017513921A (ja) * | 2014-03-03 | 2017-06-01 | アーチャルジー、スジャータ | ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質 |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| HRP20230528T1 (hr) * | 2016-03-22 | 2023-08-04 | F. Hoffmann - La Roche Ag | Bispecifične molekule t stanica aktivirane proteazom |
| US20200282074A1 (en) * | 2017-09-22 | 2020-09-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
-
2022
- 2022-07-08 IL IL309912A patent/IL309912A/en unknown
- 2022-07-08 US US18/577,452 patent/US20240368296A1/en active Pending
- 2022-07-08 CA CA3226367A patent/CA3226367A1/en active Pending
- 2022-07-08 MX MX2024000492A patent/MX2024000492A/es unknown
- 2022-07-08 EP EP22838594.4A patent/EP4366741A4/en active Pending
- 2022-07-08 KR KR1020247004338A patent/KR20240035824A/ko active Pending
- 2022-07-08 JP JP2024500492A patent/JP2024525613A/ja active Pending
- 2022-07-08 WO PCT/US2022/073541 patent/WO2023283624A2/en not_active Ceased
- 2022-07-08 AU AU2022309238A patent/AU2022309238A1/en active Pending